Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B8404e8c024fb3e5a8b887b50fbefc354> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B8404e8c024fb3e5a8b887b50fbefc354 NCIT_P378 "NCI" @default.
- B8404e8c024fb3e5a8b887b50fbefc354 type Axiom @default.
- B8404e8c024fb3e5a8b887b50fbefc354 annotatedProperty IAO_0000115 @default.
- B8404e8c024fb3e5a8b887b50fbefc354 annotatedSource NCIT_C171092 @default.
- B8404e8c024fb3e5a8b887b50fbefc354 annotatedTarget "A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to as of yet not fully elucidated co-stimulatory molecules, with potential immunostimulating and antineoplastic activities. Upon transfusion, autologous CD19-targeted CAR-T cells GC007F target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the release of cytotoxic molecules and the induction of tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The processing platform used, FasT (F) CAR-T, shortens the manufacturing time to produce the CAR-T cells within 24 hours." @default.